Looking for Work? Want to Help Give Away Billions of Dollars?
CIRM has two new job openings, including one for an AI whiz.
The California Stem Cell Report
An inside and independent look at the Golden State's $12 billion stem cell research program, how it works, who wins and who loses, its conflicts of interest and its changing priorities.
Live Last read · last published · next check
Latest posts
Capricor Stock Jumps 59 Percent as Firm Maneuvers to Win Approval of Duchenne Treatment
California taxpayers backing firm with $18 million
LinkedIn Video, Transparency, Accessibility: The View from the Stem Cell Trenches at CIRM
An infectious video involving the transparency of a California state biomedical research organization, whose 17,000-word genome rarely inspires influencers, caught my attention recently.
Capricor in Trouble with Feds But California Stands Apart from the Ruckus Despite $18 Million Taxpayer Investment. Why?
Here is the answer from the Golden State's stem cell and gene therapy program, which has a longterm interest in the program.
Political Media Tackle $12 Billion California Ballot Measure for Immunology Research
Not identical to the California stem cell and gene therapy agency, also a $12 billion enterprise, but some similarities
Capricor Committed to Winning Federal Go-Ahead on Treatment for Deadly Affliction that Attacks Boys and Young Men
California backing company with $18 million
Capricor's Treatment for Deadly Muscle-Wasting Disease Rebuffed by FDA Advisory Committee
15,000 boys and young men affected nationwide; California has millions of dollars riding on the Duchenne therapy
FDA-Capricor Hearing: Patients Tell a Story of Loss and Unstoppable Muscle Deterioration
Holding a pencil, feeding themselves and dignity are major goals for patients
Capricor-FDA Hearing: Public to be Heard Next, Vote on Capricor May Come by Midafternoon
The FDA-Capricor hearing in Maryland is beginning its afternoon session after a lunch break.
FDA Capricor Hearing: Company Says Lightning Does Not Strike Three Times in Same Place
Consistent favorable results not coincidental